ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Huadong Medicine Co., Ltd. clinical trials

Part of China Grand Enterprises, Inc., which holds 41.77% as of 2021-12-31. Source

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 62 studies whose lead sponsor is Huadong Medicine Co., Ltd. or one of 3 companies grouped under it. 46 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 17, 2026.

Our grouping of 3 registry names, not the registry’s. See them and correct one ↓

Compare Huadong Medicine with Eli Lilly and Innovent Biologics →

Pipeline: 17 programs

Each counted once: 17 with a study Huadong Medicine Co., Ltd. leads registered in the last two years.

  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4 (approved, new studies)

The 5 of 8 with the most live studies.

Program
HDM1002Phase 3 · 11 live · Diabetes Mellitus, Type 2 · primary completion Feb 2027☆ Track
HDM1005Phase 3 · 10 live · Obesity · primary completion Dec 2026☆ Track
DR10624Phase 3 · 4 live · Hypertriglyceridemia · primary completion Apr 2028☆ Track
RoflumilastPhase 3 · 1 live · Pulmonary Disease, Chronic Obstructive · primary completion Jun 2027☆ Track
HDM1702Phase 3 · 1 live · Obesity☆ Track

3 more in phase 3 — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

“Registry” is the highest phase of Huadong Medicine Co., Ltd.’s own registered studies; Huadong Medicine Co., Ltd.’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Huadong Medicine Co., Ltd.’s studies test, most open studies first — 16 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 6 more

Coming up

16 of Huadong Medicine Co., Ltd.’s studies under way reach primary completion within a year, 4 of them phase 3. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 2D
  3. 1J’27
  4. 2F
  5. M
  6. 2A
  7. M
  8. 1J
  9. 2J
  10. 3A
  11. S
  12. 2O
  13. 1N

The 12 nearest

Show 7 more

Add all 16 to your calendar (.ics) → With an account.

What changed recently

From the registry's own updates since Oct 20, 2026.

All 62 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now4674%Recruiting 28 · Not yet recruiting 18
  • Under way, not recruiting23%
  • Completed1118%
  • Stopped early12%
  • Status unknown or other23%

Phase

  • Phase 131
  • Phase 318
  • Phase 212
  • Phase 42

Where

  • China57
  • Hong Kong1
  • New Zealand1

Over the years

  1. 22
  2. 23
  3. 24
  4. 2025
  5. 1926

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Huadong Medicine Co., Ltd.

  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    50 studies →
  • Zhejiang Doer Biologics Co., Ltd.
    Acquired — became part of Huadong Medicine Co., Ltd., Apr 2021 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    9 studies →
  • Sinclair Pharmaceuticals Limited
    Acquired
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →

Focus areas

Conditions Huadong Medicine Co., Ltd. leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 62. Browse all 62 →